Company: SHPH
Filing Date: 2025-03-31
Form Type: DEF 14A
Source: 0001641172-25-001889
Chunk: 1

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-03-31
Form: DEF 14A
Chunk 1
---
 the first patients
were dosed, enrollment into the clinical trial has been robust and has met all expectations. As of writing this letter, we have achieved 43% enrollment in the initial randomized
phase of the clinical trial with a total enrollment of 17 of the initial 40 patients. Further, 11 of the 40 patients have completed all
seven cycles. Our objective is to finalize enrollment later this year with follow up and data read out in 2026.

Leading up to trial
commencement, we successfully onboarded all six nationally recognized, East Coast cancer centers. The six centers were chosen for their recognized state-of-the-art
cancer care and the availability of patients presenting with the most aggressive form of brain tumors – IDH wild-type,
methylation negative glioblastoma, the target of the clinical trial.

As a reminder, the Phase
2 clinical trial design initially randomizes 40 patients into two different dose levels of drug, with 20 patients receiving 1,200 mg/day
and 20 patients receiving 960 mg/day, to determine an optimal dose for use in glioblastoma patients in combination with RT. After the
optimal dose is identified, 14 additional patients will be enrolled at the optimal dose to reach statistical significance with the end-point
demonstrating increased survival as compared to historical controls.

This clinical trial is critical to the broader radiation therapy industry as we look to leverage radiation sensitizers to increase
cancer cure rates, prolong patient survival and improve quality of life for patients suffering from glioblastoma. I look forward to continued
trial execution as we aim to improve the lives of millions of patients impacted by cancer and to bring hope to patients and families
around the world.

ADVANCEMENT OF A ROBUST DEVELOPMENT PORTFOLIO

Our primary focus is
on our lead therapeutic Ropidoxuridine program. However, it remains important to understand the depth of development stage assets across
both cancer Therapeutics and Diagnostics.

THERAPEUTICS

Within Therapeutics,
after Ropidoxuridine, the second priority has been focused on our HDAC6 selective inhibitor SP-2-225. During the past year, we have contracted
with Dr. Alejandro Villagra’s laboratory at Georgetown University to perform in vivo studies of HDAC6 inhibition in 4T1 syngeneic
mouse breast cancers. Tumor growth delay has
been observed, and validation experiments have
been completed. SP-2-